MK-677 (Ibutamoren) vs Dihexa
Side-by-side comparison of key properties, dosing, and research.
Growth Hormone Peptides
MK-677 (Ibutamoren)Cognitive Enhancement
Dihexa- Summary
- MK-677 (Ibutamoren) is an orally active, non-peptide ghrelin receptor agonist that increases growth hormone and IGF-1 levels. Unlike injectable GHRPs, it can be taken orally and has a 24-hour half-life, making it convenient for sustained GH optimization.
- Dihexa is a potent experimental oligopeptide derived from angiotensin IV that dramatically enhances synaptogenesis. Preclinical research shows cognitive enhancement orders of magnitude more potent than BDNF — it is considered one of the most powerful nootropic compounds in research, but has very limited human safety data.
- Half-Life
- 24 hours
- Unknown (limited pharmacokinetic data)
- Admin Route
- Oral
- Oral, SubQ, Topical
- Research
- —
- —
- Typical Dose
- 10–25 mg
- 5–10 mg
- Frequency
- Once daily
- Daily
- Key Benefits
- Increases lean muscle mass
- Enhances bone density
- Improves sleep quality and REM sleep
- Accelerates recovery from training
- Increases appetite
- May improve skin elasticity and appearance
- Supports fat loss while maintaining muscle
- Oral administration — no injections required
- 24-hour half-life allows once-daily dosing
- Dramatically increases synapse formation (potentially 10 million× more potent than BDNF in animal models)
- Enhances memory and learning
- May reverse cognitive decline
- Improves neuroplasticity and executive function
- Long-lasting cognitive benefits from short courses
- Potential therapeutic agent for Alzheimer's
- Side Effects
- Increased appetite (significant in some users)
- Water retention and puffiness
- Elevated blood glucose / insulin resistance (monitor in diabetics)
- Lethargy initially
- +2 more
- Headache
- Irritability
- Brain fog during washout period
- Unknown long-term effects (insufficient data)
- Stacks With
- —
- —